Eisai to Present Data on Oncology Pipeline and Products at ASCO20 Annual Meeting

May 14, 2020 09:22 JST

Source: Eisai

TOKYO, May 14, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that presentations on a series of abstracts regarding its in-house discovered lenvatinib mesylate (multikinase inhibitor, product name: LENVIMA , "lenvatinib") and eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: HALAVEN , "eribulin") will be given at the American Society of Clinical Oncology (ASCO20 Virtual Scientific Program(1)), from May 29 to 31, 2020.

At this year's meeting, the final results of two studies will be presented on the combination therapy of lenvatinib with the anti-PD-1 antibody KEYTRUDA (generic name: pembrolizumab, "pembrolizumab") from Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada). One is the oral presentation of the metastatic renal cell carcinoma cohort (Abstract number: 5008) of Study 111 / KEYNOTE-146, and the other is the poster discussion presentation of the first-line therapy for unresectable hepatocellular carcinoma (Abstract number: 4519) in Study 116 / KEYNOTE-524(2).

In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.

Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer. Eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, and aims to make continuous efforts to meet the diversified needs of and increase the benefits provided to patients with cancer, their families, and healthcare professionals.

(1) Presentation materials will be made available on demand via ASCO's website at 8:00 AM on May 29th (ET).
(2) This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds and investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.

Contact:

Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120

Source: Eisai
Sectors: BioTech

Related Press Release

FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review

January 26 2026 10:37 JST

Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time

January 21 2026 15:44 JST

Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan

January 13 2026 08:50 JST

Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China

January 06 2026 09:43 JST

Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year

December 11 2025 18:41 JST

"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List

December 09 2025 17:51 JST

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025

December 04 2025 17:36 JST

New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

December 03 2025 17:19 JST

Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025

December 02 2025 23:01 JST

Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan

November 28 2025 22:00 JST

More Press release >>

Latest Press Release

The 55-Point Gap: Measuring What Matters in Automotive Impact
Feb 04, 2026 18:00 JST

FWD Group survey reveals over 70 per cent of Asia's middle-class feel anxiety about financial wellbeing, preventing longer-term planning
Feb 04, 2026 13:30 JST

Honda Co-developing Automobile SoC with U.S.-based Mythic to Accelerate Research to Enhance AI Computing Performance and Energy Efficiency

Feb 04, 2026 11:32 JST

DENSO Announces Third Quarter Financial Results
Feb 03, 2026 19:36 JST

Fujitsu's Takane LLM successfully piloted in central government agency to streamline public comment operations
Feb 03, 2026 11:14 JST

EAGLE Trial Shows Olympus(R) CADDIE(TM) AI Solution Aids in the Detection of High-Risk and Hard-to-Detect Colorectal Lesions
Feb 03, 2026 10:00 JST

SGL Golf Launches in U.S. Market to Meet Demand for Autonomous Course Management Solutions
Feb 03, 2026 03:00 JST

Lockheed Martin and Fujitsu to accelerate dual-use technology development
Feb 02, 2026 16:29 JST

Fujitsu introduces biometric authentication service for SMBC Nikko Securities Online Trading
Feb 02, 2026 14:30 JST

JCB Launches Usage Promotion Campaign for Inbound Visitors in Fukuoka's Tenjin Area
Feb 02, 2026 10:00 JST

NTT DOCOMO Concludes Partnership Agreement with Aduna to Advance Global Network API Expansion
Jan 30, 2026 22:50 JST

ANIME TOKYO STATION ON ROBLOX: Commemorating the One-Year Anniversary with Gifts and a Wealth of Add-on Content
Jan 30, 2026 09:00 JST

MAZDA CX-5 Achieves Five Million Units in Global Production and Sales
Jan 29, 2026 16:15 JST

The Executive Centre Celebrates 25 Years in Japan: A Commitment to Long-Term Growth and Investment
Jan 29, 2026 12:00 JST

Hitachi reinvents Ellipse Enterprise Asset Management (EAM) solution with Microsoft's AI-enabled technology to improve critical infrastructure resilience
Jan 29, 2026 10:14 JST

TANAKA Recognized as a "Tokyo Sports Promotion Company" for the 11th Consecutive Year
Jan 28, 2026 22:00 JST

NTT, DOCOMO, and NTT DATA to Exhibit at MWC Barcelona 2026
Jan 28, 2026 18:29 JST

MHI Thermal Systems Receives "Minister of Economy, Trade and Industry Award" and MHI's Aerospace Parts Factory Receives "Agency for Natural Resources and Energy Commissioner's Award" at 2025 Energy Conservation Grand Prize Awards
Jan 28, 2026 18:08 JST

Mitsubishi Power Completes GTCC Upgraded Reliability Package at VPI's Damhead Creek Power Station
Jan 28, 2026 17:58 JST

Fujitsu and Tokai National Higher Education and Research System develop space weather prediction capabilities technology leveraging AI
Jan 28, 2026 10:55 JST

More Latest Release >>